- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04568668
Evaluating ActionADE in Reducing Adverse Drug Reactions
Implementing and Evaluating ActionADE to Transform Medication Safety Among Patients With Adverse Drug Reactions
Repeat exposures to culprit medications are a common cause of preventable adverse drug events. Health information technologies have the potential to reduce repeat adverse drug events by improving information continuity. However, they rarely interoperate to ensure providers can view adverse drug events documented in other systems. The investigators designed ActionADE to enable rapid documentation of adverse drug events, and communication of standardized information across health sectors by integrating ActionADE with legacy systems.
The investigators will leverage ActionADE's implementation to conduct a randomized trial on patients diagnosed with adverse drug reactions in the main trial. This study will take place in Vancouver, British Columbia, Canada.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Medication use is rising due to an aging population and expanding treatment indications for chronic diseases. Simultaneously, adverse drug events-harmful and unintended events related to medication use or misuse-have increased. In Canada, adverse events to outpatient medications cause over two million emergency department visits and 700,000 hospital admissions, costing over $1 billion in healthcare expenditures annually. Optimizing the benefits of medications while limiting their potential for harm is a public health priority across patient populations, health settings and medical disciplines.
Patients with adverse drug events often seek care in hospitals due to the unexpected and serious nature of these events. After assessment and treatment, patients are discharged back into the care of a community-based provider who often cannot access the hospital's medical record, may not receive a legible or detailed discharge summary, and is at risk of either re-starting the culprit medication for chronic disease management in the case of an adverse drug reaction. The investigators developed ActionADE to address this type of information discontinuity. ActionADE was integrated to a province-wide network that links all pharmacies in British Columbia to a central data system, allowing users to see their patient's medication dispensing history.
The investigators will conduct a triple-blind randomized controlled trial to evaluate the effectiveness of ActionADE on preventing subsequent adverse drug reactions. The trial will take place in two urban tertiary care (Vancouver General and Saint Paul's Hospitals) and one urban community hospital (Lions Gate Hospital) within the Greater Vancouver area, in British Columbia, Canada. Other hospitals may be added to accelerate recruitment into the trial if approved by the British Columbia Ministry of Health.
The primary objective of the main trial is to evaluate the effect of providing information continuity about adverse drug reactions using ActionADE on culprit drug re-dispensations over 12 months compared to standard care. Secondary objectives are to evaluate the effect on outpatient and emergency department visits, admissions, hospital-days and mortality.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jeffrey P Hau, MSc
- Phone Number: 62270 6048754111
- Email: jeffrey.hau@ubc.ca
Study Contact Backup
- Name: Corinne M Hohl, MD,MSc
- Phone Number: 63467 6048754111
- Email: corinne.hohl@ubc.ca
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults 19 years of age or older presenting to the participating emergency departments with an adverse drug reaction to a prescribed outpatient medication that was reported in ActionADE.
Exclusion Criteria:
- Patients whose adverse drug event is categorized as life threatening will be excluded.
- Patients without a Provincial Health Number will be excluded as this will prevent linkage with PharmaNet and other administrative data for outcomes ascertainment.
- Patients diagnosed with adverse drug events to culprit medications not on the provincial formulary will be excluded as we will not be able to ascertain re-dispensations outcomes for these medications using PharmaNet data.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ADE information transmitted to PharmaNet
Patients in the experimental arm will have standardized adverse drug event information documented in ActionADE transmitted to and stored in PharmaNet, British Columbia's medication dispensing database.
The adverse drug event information will become visible to any subsequent healthcare provider who accesses the patient's PharmaNet profile.
Community pharmacy software will import the adverse drug event information such that community pharmacists can view the adverse drug event information prior to dispensing medications.
|
ActionADE is a software application that allows healthcare providers to document standardized adverse drug event information in a user-friendly and standardized manner. We integrated ActionADE uni-directionally with PharmaNet, a secure province-wide network that links all pharmacies in British Columbia to a central data system. This allows care providers to pull in demographic information and visualize their patient's medication dispensing history. In 2020, we enabled bi-directional integration with PharmaNet allowing clinicians to transmit standardized adverse drug event information back to the PharmaNet database. The three dominant community pharmacy systems in the geographic area of the trial will display the adverse drug event information in their systems, and generate patient-specific medication-level alerts when pharmacists attempt to re-dispense a culprit medication. |
No Intervention: Standard care (ADE information retained locally)
Patients in the control group will have their adverse drug event information recorded in ActionADE, and their information will be retained locally, as is the current standard of care.
This means that their adverse drug event information will not be visible to other providers via PharmaNet.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Culprit or same-class medication re-dispensing during follow-up
Time Frame: 12 months
|
The summary measure will be the proportion of patients with a culprit medication re-dispensation within 12 months.
The effect measure will be the between-group difference in the proportion with a 12 month re-dispensation.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hospital visits
Time Frame: 12 months
|
Number of outpatient and emergency visits
|
12 months
|
Hospital stay
Time Frame: 12 months
|
Number of hospital-days during hospital admissions.
|
12 months
|
Mortality
Time Frame: 12 months
|
Number of all cause mortality during follow-up.
|
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Corinne M Hohl, MD, MSc, University of British Columbia
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H18-01332
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adverse Drug Event
-
University of RochesterAgency for Healthcare Research and Quality (AHRQ)CompletedAdverse Drug Event, Potential Adverse Drug Event, and Quality MeasuresUnited States
-
University of PittsburghRANDCompletedAdverse Drug EventsUnited States
-
US Department of Veterans AffairsCompletedAdverse Drug EventsUnited States
-
Westview Physician CollaborativeCompletedAdverse Drug EventsCanada
-
Indiana UniversityBrigham and Women's HospitalCompleted
-
Sultan Qaboos UniversityCompleted
-
VA Office of Research and DevelopmentCompletedAdverse Drug EventsUnited States
-
Ottawa Hospital Research InstituteMcGill University; Canadian Institutes of Health Research (CIHR)CompletedAdverse Drug EventsCanada
-
Intermountain Health Care, Inc.Completed
-
Cedars-Sinai Medical CenterNational Institutes of Health (NIH); National Institute on Aging (NIA)Completed
Clinical Trials on ActionADE
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Vancouver Coastal Health; Ministry...Not yet recruitingAdverse Drug Event | Non-Adherence, Medication